Corticosteroid-independent inhibition of tumor necrosis factor production by the neuropeptide urocortin

American Journal of Physiology - Endocrinology and Metabolism

Volumn 275, Issue 5 38-5, 1998, Pages

  Agnello, Davide ^a   Bertini, Riccardo ^b   Sacco, Silvano ^a   Meazza, Cristina ^a   Villa, Pia ^a,c   Ghezzi, Pietro ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Chemistry Section   (Italy)

^c CNR   (Italy)

Author keywords

Corticotropin releasing factor; Cytokines; Hypothalamus pituitary adrenal axis; Inflammation; Interleukin 1; Interleukin 6; Kupffer cells; Lipopolysaccharide

Indexed keywords

CORTICOSTEROID; CORTICOTROPIN RELEASING FACTOR; CYANOKETONE; CYCLIC AMP; INTERLEUKIN 1BETA; INTERLEUKIN 6; NEUROPEPTIDE; TUMOR NECROSIS FACTOR; UROCORTIN;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CORTICOSTERONE BLOOD LEVEL; CYTOKINE PRODUCTION; DOSE RESPONSE; HORMONE ACTION; HORMONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; KUPFFER CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 0031761855     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.1998.275.5.e757     Document Type: Article

References (17)

1. Aggarwal, B. B., W. J. Khor, P. E. Hass, B. Moffat, S. A. Spencer, J. Henzel, S. Bringman, G. E. Nedwin, D. V. Goeddel, and R. N. Harkins. Human tumor necrosis factor. Production, purification and characterization. J. Biol. Chem. 260: 2345-2354, 1985.
2. Bertini, R., M. Bianchi, and P. Ghezzi. Adrenalectomy sensitizes mice to the lethal effects of interleukin 1 and tumor necrosis factor. J. Exp. Med. 167: 1708-1712, 1988.
3. Boehme, S.A.,A. Gaur, P. D. Crowe, X. J. Liu, S. Tamraz, T. Wong, A. Pahuja, N. Ling, W. Vale, E. B. De Souza, and P. J. Conlon. Immunosuppressive phenotype of corticotropin-releasing factor transgenic mice is reversed by adrenalectomy. Cell. Immunol. 176: 103-112, 1997.
4. Chensue, S. W., P. D. Terebuh, D. G. Remick, W. E. Scales, and S. L. Kunkel. In vivo biologic and immunohistochemical analysis of interleukin-1 alpha, beta and tumor necrosis factor during experimental endotoxemia. Am. J. Pathol. 138: 395-402, 1991.
5. Chrousos, G. P. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N. Engl. J. Med. 332: 1351-1362, 1995.
6. Correa, S. G., C. M. Riera, J. Spiess, and I. D. Bianco. Modulation of the inflammatory response by corticotropinreleasing factor. Eur. J. Pharmacol. 319: 85-90, 1997.
7. Dave, J. R., L. E. Eiden, and R. L. Eskay. Corticotropinreleasing factor binding to peripheral tissue and activation of the adenylate cyclase-adenosine 3′,5′'-monophosphate system. Endocrinology 116: 2152-2159, 1985.
8. Elliott, M. J., R. N. Maini, M. Feldmann, J. R. Halden, C. Antoni, J. S. Smolen, B. Leeb, F. C. Breedveld, J. D. Macfarlane, H. Bijl, and J. N. Woody. Randomised doubleblind comparison of chimeric monoclonal antibody to tumour necrosis factor ot (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105-1110, 1994.
9. Endres, S., H.-J. Fulle, B. Sinha, D. Stoll, C. A. Dinarello, R. Gerzer, and P. C. Weber. Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-α and interleukin-1β by human mononuclear cells. Immunology 72: 56-60, 1991.
10. Fantuzzi, G., E. Di Santo, S. Sacco, F. Benigni, and P. Ghezzi. Role of the hypothalamus-pituitary-adrenal axis in the regulation of tumor necrosis factor production in mice: effect of stress and inhibition of endogenous glucocorticoids. J. Immunol. 155: 3552-3555, 1995.
11. Fantuzzi, G., and P. Ghezzi. Glucocorticoids as cytokine inhibitors: role in neuroendocrine control and therapy of inflammatory diseases. Medial. Inflamm. 2: 263-270, 1993.
12. Kelley, D. M., A. Lichtenstein, J. Wang, A. N. Taylor, and S. M. Dubinett. Corticotropin-releasing factor reduces lipopolysaccharide-induced pulmonary vascular leak. Immunopharmacol. Immunotoxicol. 16: 139-148, 1994.
13. Labeur, M. S., E. Artz, G. J. Wiegers, F. Holsboer, and J. M. Reul. Long-term intracerebroventricular corticotropin-releasing hormone administration induces distinct changes in rat splenocyte activation and cytokine expression. Endocrinology 136: 2678-2688, 1995.
14. Lipton, J. M., and A. Catania. Anti-inflammatory actions of the neuroimmunomodulator α-MSH. Immunol. Today 18: 140-145, 1997.
15. Lovenberg, T., D. Chalmers, C. Liu, and E. De Souza. CRF2α and CRF2β receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology 136: 4139-4142, 1995.
16. Molnar-Kimber, K. L., L. Yonno, R. J. Heaslip, and B. M. Weichman. Differential regulation of TNF-α and IL-1β production from endotoxin stimulated human monocytes by phosphodiesterase inhibitors. Medial. Inflamm. 1: 411-417, 1992.
17. Poliak, S., F. Mor, P. Conlon, T. Wong, N. Ling, J. Rivier, W. Vale, and L. Steinman. The neuropeptides corticotropinreleasing factor and urocortin suppress encephalomyelitis via effects on both the hypothalamic-pituitary-adrenal axis and the immune system. J. Immunol. 158: 5751-5756, 1997.